NCT07807995

A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-09-18Est. Completion: 2029-12-28

Enrollment target: 605 participants

Contact

Medical Informationmedicalinfo@vrtx.com 617-341-6777

Other microbiome trials you might be interested in

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsPhase 2Recruiting

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine CarcinomaBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct CarcinomaInvasive Bladder Giant Cell Urothelial CarcinomaInvasive Bladder Lymphoepithelioma-Like CarcinomaInvasive Bladder Nested Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Bladder Urothelial Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.